In trading on Wednesday, shares of Zurn Elkay Water Solutions Corp (Symbol: ZWS) crossed above their 200 day moving average of $35.89, changing hands as high as $36.15 per share. Zurn Elkay Water Solutions Corp shares are currently trading up about 2% on the day. The chart below shows the one year performance of ZWS shares, versus its 200 day moving average: Looking at the chart above, ZWS's low point in its 52 week range is $27.74 per share, with $41.15 as the 52 week high point — that compares with a last trade of $36.22. Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

北京时间3月24日凌晨，美股周一收高，但三大指数均已从盘中最高点大幅回落。美国总统特朗普表示美伊双方已举行会谈，且他已叫停对伊朗发电厂及能源基础设施的打击行动，为投资者带来希望——此前推高油价并引发全球衰退担忧的中东冲突或正接近尾声。 道指涨631.00点，涨幅为1.38%，报46208.47点；纳指涨299.15点，涨幅为1.38%，报21946.76点；标普500指数涨74.52点，涨幅为1.15%，报6581.00点。 三大美国股指盘中高点涨幅均超2%。道指最高上涨逾1100点，涨幅达2.5%； 纳斯达克 指数最高上涨2.5%；标普500指数最高上涨2.2%。 在特朗普总统表示近期与伊朗的会谈“富有成效”并暂时叫停计划中的军事打击后，芯片板块普涨。这一基调转变有助于缓解市场对能源供应中断及更广泛地缘政治影响的担忧——这些因素此前一直压制着市场情绪。 这场缓解性反弹迅速蔓延至整个半导体板块。博通、 英特尔 、 德州仪器 、迈威尔科技、 ADI > 亚德诺 半导体及 高通 均录得上涨，其中德州仪器还受益于其新数据中心模块的发布。 特朗普周一上午在Truth Social平台发文前，受油价飙升及伊朗冲突持续时间不确定性困扰，期货市场原本预示股市将进一步下跌。但在特朗普表态后，道指期货一度飙升逾1100点。 特朗普发文后原油价格下跌，西得克萨斯中质原油期货跌幅逾11%，至每桶87美元左右；国际基准布伦特原油期货跌幅亦逾11%，至每桶98美元。 特朗普在帖子中写道：“我很高兴地报告，美利坚合众国与伊朗在过去两天里，就全面、彻底解决我们在中东的敌对状态，进行了非常良好且富有成效的对话。” 他补充道：“基于这些深入、细致且富有建设性对话的基调与氛围——本周此类对话还将继续——我已指示国防部，将针对伊朗发电厂及能源基础设施的所有军事打击行动推迟五天，此举取决于后续会谈与讨论的进展。” 周一上午晚些时候，特朗普表示伊朗和美国都希望“达成协议”，两国“今天可能会通过电话沟通”。 但在伊朗官方媒体称美伊之间未举行直接会谈后，美股三大股指均从盘中高点回落。 在媒体传出美国正同伊朗伊斯兰议会议长卡利巴夫进行会谈的消息后，伊朗方面迅速予以否认，军方人士还称战斗将持续。 据央视新闻，伊朗方面否认卡利巴夫正在参加与美国方面的谈判。 据新华社，卡利巴夫23日周一在社交媒体发文，否认已经与美国举...

Apogee Therapeutics ( APGE ) announced on Monday that it has commenced an underwritten public offering of $300 million of shares of its common stock. In addition, Apogee expects to grant the underwriters a 30-day option to purchase up to an additional $45 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. Apogee intends to use the net proceeds from this offering, together with its existing cash, cash equivalents, marketable securities, and long-term marketable securities, to fund preclinical studies, clinical trials, manufacturing, and commercial readiness activities supporting its antibody programs, as well as for additional research and development activities, capital expenditures, working capital, and general corporate purposes. APGE +0.10% after hours to $79.21. Source: Press Release More on Apogee Therapeutics Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis - Slideshow Apogee Therapeutics: 2026 Inflection Point In Immunology Apogee Therapeutics, Inc. (APGE) Discusses Interim Phase Ib Results of Zumilokibart for Mild-to-Moderate Asthma and Pipeline Developments Transcript Apogee Therapeutics rises on positive phase 2 data for Zumilokibart in atopic dermatitis Seeking Alpha’s Quant Rating on Apogee Therapeutics

Retailer-owned hardware cooperatives True Value Hardware and Ace Hardware have struggled to compete with the giant home-improvement retailers Home Depot, Lowe's, and Amazon, and in some cases, their chain stores have lost the battle and closed businesses. Home Depot dominated the home improvement ...

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Apple (NasdaqGS:AAPL) secured a legal win that allows continued U.S. sales of its new Apple Watch models in an ongoing patent dispute. A U.S. trade tribunal found that the latest Apple Watches do not infringe Masimo's patents, removing the immediate risk of an import ban on these devices. The decision directly affects Apple's wearables revenue stream and keeps a core product line available in a key market while legal proceedings continue. For you as an investor following NasdaqGS:AAPL, this ruling means Apple's current Apple Watch lineup can remain on U.S. shelves, which keeps one of its major hardware categories intact. The watch sits alongside the iPhone, Mac, iPad, and services as part of a broader ecosystem that encourages customers to stay within Apple’s product family. Looking ahead, the decision provides operational clarity on Apple Watch sales in the U.S., even though the wider legal dispute is still active. Investors will likely focus on how Apple manages ongoing intellectual property risks around its health and wearables features and how that may influence future product design choices. Stay updated on the most important news stories for Apple by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Apple. NasdaqGS:AAPL 1-Year Stock Price Chart Is Apple's balance sheet strong enough for future acquisitions? Dive into our detailed financial health analysis. Quick Assessment ⚖️ Price vs Analyst Target : At US$247.99, the share price is about 16% below the US$295.44 analyst target. ⚖️ Simply Wall St Valuation : Shares are described as trading close to estimated fair value. ❌ Recent Momentum: The 30 day return of about 6.3% decline signals weak short term momentum. To decide whether to buy, sell or hold Apple, you can review the latest valuation work in Simply Wall S...

格隆汇3月24日｜新西兰联储行长布雷曼：如果中期通胀或通胀预期受到影响，适当的政策回应可能是提高利率，以防止出现这些第二轮效应。

Source: Bloomberg, 0:00

格隆汇3月24日｜道琼斯指数3月23日（周一）收盘上涨631.12点，涨幅1.38%，报46208.59点； 标普500指数3月23日（周一）收盘上涨74.52点，涨幅1.15%，报6581.00点； 纳斯达克综合指数3月23日（周一）收盘上涨299.15点，涨幅1.38%，报21946.76点。

A Mobilicom Tier-1 defense customer won a U.S. Department of War (DoW) Program of Record, indicating a potential production scale orders for the next 5 years Cash and cash equivalents surge 120% to $19.1 million following $12.6 million in 2025 warrants exercise and equity raises With revenues up year-over-year at $3.4 million, monthly operating cash burn was cut by 41% to ~$159K — lowest in Company history — with zero-debt on balance sheet Launch of industry-first Secured Autonomy™ cybersecurity framework, multiple new design wins across Europe, Middle East and South Asia, and expanded U.S. Tier-1 drone production-scale orders drive multi-market momentum Webcast scheduled for 4:30 pm EST today PALO ALTO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Mobilicom Limited (Nasdaq: MOB, MOBBW) (“Mobilicom” or the “Company”), a provider of cybersecurity and robust solutions for drones and robotics, today announced reported financial results for the year ended December 31, 2025. “2025 marked another year of strong growth and strategic progress for Mobilicom,” said Mobilicom Founder and CEO Oren Elkayam. “We expanded relationships with Tier-1 customers, secured multiple design wins across global defense and robotics markets, and introduced our Secured Autonomy™ framework—an industry-first cybersecurity solution designed to protect mission-critical autonomous systems. Together with Aitech, we also delivered the first AI-powered Secured Autonomy computing systems, further strengthening our position in secure autonomous platforms and positioning Mobilicom to potentially capture greater recurring software revenue as the autonomy market continues to accelerate. With our differentiated technology, expanding customer base, and growing product pipeline, we believe we are well positioned to drive continued growth and long-term shareholder value.” Operational Highlights and Recent Business Developments During 2025, Mobilicom continued to expand its global presence and deepen engagement w...

Revenue Growth Driving Group to Record EBITDA • Revenue of $186.5 million with organic revenue growth of 6.2% • Record Adjusted EBITDA of $45.4 million, up 17.7% year over year, achieved at a margin of 24.3% • Successfully completed our $45.8 million IPO in the US and dual-listing on Nasdaq in January 2026 • Net Debt of $26.6 million has reverted to a Net Cash position in 2026 • Completed two acquisitions in 2025, further expanding PPHC's capabilities and geographic reach WASHINGTON, March 23, 2026 (GLOBE NEWSWIRE) -- Public Policy Holding Company, Inc. ("PPHC," "Company," "Group") (Nasdaq: PPHC and AIM: PPHC.L), a leading global strategic communications provider offering a comprehensive range of advisory services in the areas of Government Relations, Corporate Communications, and Public Affairs, today reported unaudited financial results for the year ended December 31, 2025 ("FY 2025"). Q4 2025 Financial Highlights • Q4 revenue increased 27.8% over the prior period to $49.9 million, with organic growth contributing 5.4%. • GAAP Net Loss of $(15.2) million compared to $(6.7) million in Q4 2024. • Adjusted EBITDA of $12.4 million, up 27.1% over the prior period, achieved at a 24.9% margin. • Adjusted Net Income of $11.3 million was up 66.1%. • GAAP Basic and diluted loss per share of $(0.86) compared to $(0.46) in Q4 2024. • Adjusted fully diluted EPS of $0.42 was up $0.15 or 58.0%. FY 2025 Financial Highlights • FY revenue increased 24.7% to $186.5 million, with organic growth contributing 6.2%. • GAAP Net Loss of $(39.0) million compared to $(24.0) in 2024. • Adjusted EBITDA of $45.4 million, up 17.7%, and achieved at a 24.3% margin. • Adjusted Net Income of $36.6 million was up 32.1%. • GAAP Basic and diluted loss per share of $(2.37) compared to $(2.34) in 2024. • Adjusted fully diluted EPS of $1.39 was up $0.27 or 24.7%. • GAAP Net Cash Provided by Operations of $24.8 million compared to $16.4 million in 2024. • Adjusted Free Cash Flow of $36.9 million (2024: $2...

格隆汇3月24日｜新西兰联储行长布雷曼：货币政策能够也应当确保暂时的通胀飙升不会演变为持久的通胀压力。

Meta Platforms (META) exec Javier Oliván reports multiple share sales under Rule 144 Stock Titan

格隆汇3月24日｜新西兰联储行长布雷曼：货币政策必须具有前瞻性，并着眼于中期通胀压力。

May NY world sugar #11 (SBK26) on Monday closed down -0.18 (-1.15%), and May London ICE white sugar #5 (SWK26) closed down -2.70 (-0.60%). Monday's plunge in crude oil prices (CLK26) by more than -9% sparked long liquidation in sugar futures. The weakness in crude prices undercuts ethanol prices and may encourage the world's sugar mills to decrease ethanol production and boost sugar output. Don’t Miss a Day: Sugar prices still have some support amid supply disruptions from the closure of the Strait of Hormuz. According to Covrig Analytics, the closure of the strait has curbed approximately 6% of the world's sugar trade, constraining refined sugar output. Earlier this month, sugar prices plunged to 5.5-year nearest-futures lows on concern that a global sugar surplus will persist. On February 11, analysts from sugar trader Czarnikow said they expect a global sugar surplus of 3.4 MMT in the 2026/27 crop year, following an 8.3 MMT surplus in 2025/26. Also, Green Pool Commodity Specialists said on January 29 that they expect a 2.74 MMT global sugar surplus for 2025/26 and a 156,000 MT surplus for 2026/27. Meanwhile, StoneX said February 13 that it expects a global sugar surplus of 2.9 MMT in 2025/26. The International Sugar Organization (ISO) on February 27 forecasted a +1.22 MMT (million metric ton) sugar surplus in 2025-26, following a -3.46 MMT deficit in 2024-25. ISO said the surplus is being driven by increased sugar production in India, Thailand, and Pakistan. ISO is forecasting a +3.0% y/y rise in global sugar production to 181.3 million MMT in 2025-26. Signs of lower sugar output in Brazil are supportive of sugar prices, after Unica on February 18 reported that sugar production in Brazil's Center-South in the second half of January fell by -36% y/y to only 5,000 MT. However, cumulative 2025-26 Center-South sugar output through January rose +0.9% y/y to 40.24 MMT. The Indian Sugar and Bio-energy Manufacturers Association (ISMA) reported last Tuesday that India's 2...

Expect to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Scheduled to present retinal vascular research on SZN-8141 at the upcoming 2026 ARVO Annual Meeting Received notice of achievement of research milestone by Boehringer Ingelheim for SZN-413, triggering $5 million milestone payment Strengthened key leadership roles in 2025 to support long-term ophthalmology strategy SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced financial results for the fourth quarter and full year 2025 and provided a business update. Business Highlights Surrozen remains focused on advancing a new generation of ophthalmology therapeutics that are built on a foundation of Wnt pathway biology. Surrozen’s pipeline leverages its Wnt biology expertise and antibody technologies to develop therapeutics targeting ophthalmic diseases with significant unmet medical needs. Recent Events and Upcoming 2026 Milestones Ophthalmology Pipeline Advancement: The Company continues to progress its lead candidates, SZN-8141 and SZN-8143, in retinal diseases and remains on track to submit an Investigational New Drug (IND) application for SZN-8141 in the second half of 2026 In March 2026, Boehringer Ingelheim achieved a research milestone under the agreement for SZN-413, reflecting a positive outcome of the IND-enabling GLP toxicology study. The research milestone entitles Surrozen to receive a $5.0 million payment from Boehringer Ingelheim. Scientific Presentations Highlighting Next Generation Surrozen Wnt Therapeutics for Retinal Diseases The Company presented an overview of Next Generation Wnt Therapeutics in Retinal Diseases at Eyecelerator (American Academy of Ophthalmology) Meeting and at the ...

– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 – – Company announced first wholly owned dual-payload program targeting PTK7, STRO-227, accelerating IND submission to 2026 – – Astellas-partnered iADC dual-payload program enters the clinic; patient dosing underway – – Cash, cash equivalents and marketable securities as of December 31, 2025 of $141.4 million, excluding proceeds from the recent capital raise of approximately $110 million which extended cash runway into at least the second quarter of 2028 – SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the full year 2025 and recent business highlights. “2026 is poised to be a pivotal year, propelled by disciplined clinical execution and initial data that we believe will showcase the vast potential of our proprietary ADC platform,” said Jane Chung, Sutro’s Chief Executive Officer. “We recently completed dosing the third cohort in the Phase 1 trial of STRO-004, our potential best-in-class Tissue Factor ADC, and look forward to reporting initial data mid-year. In parallel, we are advancing STRO-006, our ITGB6 ADC, and accelerating STRO-227, our wholly owned dual-payload program targeting PTK7, toward IND submission this year. In addition, patient dosing has commenced under our collaboration with Astellas Pharma for our first partnered dual-payload iADC — marking the first dual-payload program from Sutro’s platform to enter the clinic. Supported by our recent financing, continued financial stewardship, and sharpened strategic focus, we believe we are well positioned to execute across all our programs and deliver differentiated ADCs with best-in-class potential that could redefine standards of car...

Voluntary pause of the Phase 3 HERO and OLE trials evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome, further guidance on the program expected in Q2 2026 ARD-201 obesity program, including POWER and STRENGTH trials, on voluntary pause pending next steps with ARD-101; further guidance on the program expected in Q2 2026 Clinical and preclinical data from ARD-101 program published in Molecular Metabolism $110.0 million in cash, cash equivalents and short-term investments as of December 31, 2025, supports projected operations into the second quarter of 2027 SAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided pipeline and business updates. “Patient safety will always be our highest priority, and we are actively engaging with the FDA with urgency to determine the best path forward for our programs. As we evaluate next steps, we want to thank the Prader-Willi Syndrome community for its collaboration throughout this process. The community’s strength and tenacity continue to inspire our work,” said Tien Lee, M.D., Founder and Chief Executive Officer of Aardvark. “With positive clinical data, an encouraging safety profile from previous trials and our recently developed understanding of the clear blood plasma exposure-response relationship with reversible cardiac QRS prolongation, we have confidence in ARD-101. We strongly believe that ARD-101 retains its potential as a differentiated therapeutic option for hyperphagia in individuals living with PWS. We hope to resume the PWS development program in a timely manner and expect to provide further guidance on each of our programs in the second quarter of 2...

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates ABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on March 18, 2026 found no new safety signals; the analysis included 100% of patients randomized, with nearly 90% having completed the 44-week double blind maintenance trial The Company’s pivotal Phase 3 ABTECT maintenance trial evaluating obefazimod for moderately to severely active ulcerative colitis remains on track to report topline results in late Q2 2026 Abivax appointed Michael Nesrallah, MBA as Chief Commercial Officer, bringing extensive IBD leadership experience to support the Company’s next phase of growth; other key senior leadership hires made in Regulatory Affairs and Research to support continued advancements of its programs Cash, cash equivalents and short-term investments of €530.4M as of December 31, 2025; cash runway into Q4 2027 Abivax’s Annual General Meeting (“AGM”) to be held May 11, 2026, and the Company expects to report its first quarter 2026 financial results on May 25, 2026 PARIS, France – March 23, 2026 – 9:05 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, reported today its financial results for the full year ended December 31, 2025. The 2025 financial statements, approved by the Company’s Board of Directors on March 19, 2026, have been audited by the Company’s statutory auditors, and the financial reports will be filed with the French and U.S. securities regulatory authorities, respectively, on March 23, 2026. Marc de Garidel, MBA, Chief Executive Officer of Abivax, commented: “With a strong financial foundation, we are well positioned to execute on our strategic priorities and prepare for the future. We are pleased with the recent DSMB saf...

SAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2025. "2025 demonstrated the momentum we built as a business,” commented Erik Holmlin, PhD, president and CEO of Bionano. “Our routine users of optical genome mapping (OGM) and VIA™ software remain the foundation of our revenue and gross margins, and we are pleased to see continued growth in utilization among this core customer base. The global OGM community continues to show extraordinary energy, from the record attendance and engagement at the Bionano Symposium 2026 – where leading laboratories described scaling OGM workflows to potentially thousands of samples per year – to the continued expansion of the published body of clinical research evidence supporting OGM across hematologic malignancies, constitutional genetics, and cell and gene therapy applications. We also saw the 47% increase in the 2026 Clinical Lab Fee Schedule payment determination for the Category I CPT code for OGM use in hematologic malignancies take effect. Together, these developments reinforce our confidence that OGM is becoming the standard for comprehensive, genome-wide structural variant analysis, and that Bionano is well-positioned to drive continued utilization growth and sustainable progress in 2026." Q4 2025 Financial Results For the three-month period ended December 31, 2025, as compared to the same period of 2024: Reported total revenue of $8.0 million, representing a decrease of 3% from $8.2 million in the fourth quarter of 2024. Consumables and software revenues decreased 1%. The prior year period included $2.8 million in instrument revenue, compared to $2.7 million in the fourth quarter of 2025. Sold 7,554 nanochannel array flowcells in the fourth quarter of 2025, representing a decrease of 6% over the 8,058 flowcells sold in the fourth quarter of 2024. Installed 9 new OGM systems and brought 6 back to reach an...

There's reason to believe Monday's market rally could be part of a bigger rebound for the S & P 500 , according to Morgan Stanley. With its 1.2% rally on Monday, the S & P 500 came roaring back from the brink of nearly entering a 10% correction. But measured by its price-to-earnings ratio, that drawdown was even more intense than it looked on paper — good news for investors hoping for a continued recovery, said Michael Wilson, an equity strategist at the investment bank. The S & P 500's forward price-to-earnings multiple fell 15% from from its October high, Wilson said, evidence that the market has already been in a correction, and further proof that the pullback is already advanced "in both time and price," the strategist said. "Those who claim the equity market is complacent are likely only considering price as opposed to looking at valuations," Wilson said. .SPX 1D mountain S & P 500 on Monday Wilson said the valuation drawdown rivals what was seen during the manufacturing decline in 2015 and the recession scare of 2023. But this time is different, he said, because forward earnings growth has continued speeding up and is now nearing 20%. Given that, Wilson said it's unlikely that the oil spike will cause the current business expansion to end. The stock market usually sees an above-average return when earnings are accelerating and the breadth of earnings per share revisions is positive, as is the case today, he said. On average, stocks gain 3% one month out and rise 9% over the next year in these situations, according to an analysis of data going back nearly three decades. "The deceleration that is now priced appears too severe to us," Wilson said. "In other words, the market, via valuations, always gets in front of the change in growth." The S & P 500 was on the verge of a 10% correction, defined as the size of the retreat from a recent high, after Friday's 1.5% decline. But the broad index rebounded Monday after President Trump said the U.S. and Iran held "produ...

格隆汇3月24日｜新西兰联储行长布雷曼：已做好充分准备，应对中东持续冲突对我们物价稳定和金融稳定使命带来的挑战。

Supreme Court skeptical of laws counting mail-in ballots after election day toggle caption Andrew Harnik/Getty Images At the Supreme Court Monday, the conservative majority seemed ready to overturn laws in 29 states that allow mail-in votes to be counted after election day if they were post-marked by Election Day. President Trump has long railed against mail-in voting, believing -– incorrectly -- that those late votes improperly cost him the 2020 election. But citizens and politicians alike have enthusiastically embraced voting by mail. The split was illustrated in Monday's case from Mississippi. In 2020, the state legislature, by a bipartisan and nearly unanimous vote, approved a five-day grace period for counting election ballots if they were post-marked by Election Day but arrived late. Sponsor Message But in the Supreme Court Monday, the conservative justices, like Trump, seemed suspicious of extending a short grace period to count late-arriving ballots. Justices Neil Gorsuch and Amy Coney Barrett, for instance, fixated on what they deemed the possibility of voters "recalling ballots," which they said could be theoretically done by the U.S. Postal Service or other common carriers like Fedex. Mississippi Solicitor General Scott Stewart tried repeatedly to assure the Court that the state does not permit ballot recalls. But Gorsuch in particular seemed to view those assurances as unreliable. "FedEx isn't an election official," Gorsuch said. Similarly, Justice Brett Kavanaugh questioned whether a grace period to count legally cast ballots might undermine public confidence in the election process. And Justice Clarence Thomas wondered how early voting is legal. On that, however, even the Trump administration's solicitor general, D. John Sauer, conceded the validity of early voting. The larger question that seemed to divide the courts six conservatives from the three liberals was where the court should be in terms of assessing new election procedures. Why, asked Justic...

In trading on Monday, shares of AGCO Corp. (Symbol: AGCO) crossed above their 200 day moving average of $111.47, changing hands as high as $114.58 per share. AGCO Corp. shares are currently trading up about 4.4% on the day. The chart below shows the one year performance of AGCO shares, versus its 200 day moving average: Looking at the chart above, AGCO's low point in its 52 week range is $73.79 per share, with $143.78 as the 52 week high point — that compares with a last trade of $114.08. Click here to find out which 9 other stocks recently crossed above their 200 day moving average » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. Kraft Heinz Co (Symbol: KHC) presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making Kraft Heinz Co an even more interesting and timely stock to look at, is the fact that in trading on Wednesday, shares of KHC entered into oversold territory, changing hands as low as $33.03 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used to measure momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In the case of Kraft Heinz Co, the RSI reading has hit 29.5 — by comparison, the universe of dividend stocks covered by Dividend Channel currently has an average RSI of 49.7. A falling stock price — all else being equal — creates a better opportunity for dividend investors to capture a higher yield. Indeed, KHC's recent annualized dividend of 1.6/share (currently paid in quarterly installments) works out to an annual yield of 4.60% based upon the recent $34.80 share price. A bullish investor could look at KHC's 29.5 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Among the fundamental datapoints dividend investors should investigate to decide if they are bullish on KHC is its dividend history. In general, dividends are not always predictable; but, looking at the history chart below can help in judging whether the most recent dividend is likely to continue. Click here to find out what 9 other oversold dividend stocks you need to know about »...

The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. Dreyfus Strategic Municipals, Inc. (Symbol: LEO) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making Dreyfus Strategic Municipals, Inc. an even more interesting and timely stock to look at, is the fact that in trading on Monday, shares of LEO entered into oversold territory, changing hands as low as $6.15 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used to measure momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In the case of Dreyfus Strategic Municipals, Inc., the RSI reading has hit 29.4 — by comparison, the universe of dividend stocks covered by Dividend Channel currently has an average RSI of 43.9. A falling stock price — all else being equal — creates a better opportunity for dividend investors to capture a higher yield. Indeed, LEO's recent annualized dividend of 0.312/share (currently paid in monthly installments) works out to an annual yield of 5.00% based upon the recent $6.24 share price. A bullish investor could look at LEO's 29.4 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Among the fundamental datapoints dividend investors should investigate to decide if they are bullish on LEO is its dividend history. In general, dividends are not always predictable; but, looking at the history chart below can help in judging whether the most recent dividend is likely to continue. Click here to find out wha...

格隆汇3月24日｜据亲政府电视台Al Ikhbariya：叙利亚军队表示，其位于叙利亚东北部的一处基地遭到从伊拉克发射的导弹袭击。

The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. Procter & Gamble Company (Symbol: PG) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making Procter & Gamble Company an even more interesting and timely stock to look at, is the fact that in trading on Monday, shares of PG entered into oversold territory, changing hands as low as $139.21 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used to measure momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In the case of Procter & Gamble Company, the RSI reading has hit 29.5 — by comparison, the universe of dividend stocks covered by Dividend Channel currently has an average RSI of 53.7. A falling stock price — all else being equal — creates a better opportunity for dividend investors to capture a higher yield. Indeed, PG's recent annualized dividend of 4.2272/share (currently paid in quarterly installments) works out to an annual yield of 2.95% based upon the recent $143.45 share price. A bullish investor could look at PG's 29.5 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Among the fundamental datapoints dividend investors should investigate to decide if they are bullish on PG is its dividend history. In general, dividends are not always predictable; but, looking at the history chart below can help in judging whether the most recent dividend is likely to continue. Click here to find out what 9 other oversold dividend ...

Key Points Crowdstrike's Falcon cybersecurity program is a unique AI-driven counter to new cybersecurity threats. It has seen adoption from more than half of the Fortune 500 and the vast majority of state governments. Crowdstrike is growing its revenue and ARR and is nearing profitability. 10 stocks we like better than CrowdStrike › Cybersecurity is big business. Given how much of our lives are online these days, that's not exactly a hot take, but it is true. According to Grand View Research, the global cybersecurity market was worth $271.88 billion in 2025 and is expected to grow at a compound annual growth rate (CAGR) of 11.9% through 2033, when it's projected to be worth $663.24 billion. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » A big part of the reason for that growth is artificial intelligence (AI) which presents unprecedented threats to cybersecurity. Between AI-generated deepfakes or phishing emails and the fact that an AI program doesn't need to eat or sleep like a flesh-and-blood hacker, cyberthreats are proliferating at an alarming rate. It also used to be that you needed a good understanding of computer technology to be an effective hacker. With AI, pretty much anyone can do it. That's where CrowdStrike (NASDAQ: CRWD) and its Falcon product comes in. Winning the digital arms race The way Falcon works, per CrowdStrike's marketing material, is that it uses agentic AI to monitor nodes installed on machines across the company's network of customers for threats. When a threat is detected, the AI agent is capable of responding to it and helping the CrowdStrike customer's internal security team clear the network of the threat. Falcon gets cybersecurity data from all the computers it's connected to. So, if one node on the network is hit by a novel cyberattack, it might get through that on...

Astera Labs Stock Surges on AI Hopes and Hype TipRanks

Just moments after Donald Trump backed down from his threat to bomb Iran’s energy infrastructure in a Truth Social post at 7:05 a.m., oil prices plunged over 13%, Treasury yields tumbled and traders signaled that US stocks would surge at the opening bell. It almost didn’t matter that less than an hour later Iran contradicted Trump’s claim that negotiations were underway. On Wall Street, the message was clear: Trump, at least, is eager to end a war that has sent the global economy careening toward a crisis since he started it a little over three weeks ago. “If this doesn’t get resolved over the next seven to 10 days, we’re looking at a pandemic-style shut down of the global economy,” said Marko Papic , chief strategist at BCA Research . “Today’s announcement suggested Trump is aware the real economy could fall off the cliff.” The president’s move set off a wild, five-minute rally that punctuated the most volatile trading day on Wall Street since the US-Israeli war on Iran began. It also echoed the sharp reversals that traders endured last April, when Trump pulled worldwide financial markets back from the brink by pausing his trade war. Like then, his announcement was, in part, aimed at investors rattled by the fallout, according to people familiar with the matter, to head off another painful selloff just as the week began. After US markets opened on Monday, the S&P 500 jumped 2.2%, the biggest rally since May. Two-year Treasury yields at one point tumbled 0.22 percentage points from their highs to a low of 3.79%. Brent crude dropped below $100 a barrel, the dollar fell , and European stock and bond markets rebounded sharply from losses to end the day higher. Yet beneath it all lurked doubts that Trump will be able to end the war as easily as he began it. And as that sentiment gained ground, the early gains faded across markets — underscoring the president’s limited ability to jawbone investors who are bracing for a period of potentially prolonged instability in the M...